{"id":72,"date":"2025-12-05T20:09:53","date_gmt":"2025-12-05T20:09:53","guid":{"rendered":"https:\/\/pre.multilingualpress.syde.wpinfra.cloud\/de-market\/?page_id=72"},"modified":"2025-12-10T11:41:35","modified_gmt":"2025-12-10T11:41:35","slug":"komplexer-inhalt","status":"publish","type":"page","link":"https:\/\/pre.multilingualpress.syde.wpinfra.cloud\/de-market\/komplexer-inhalt\/","title":{"rendered":"Komplexer Inhalt"},"content":{"rendered":"\n
<\/span>
\n
\n

Clinical Pipeline<\/h1>\n\n\n\n

A comprehensive overview of our 2024\u20132027 drug development portfolio across oncology, immunology, and rare diseases.<\/p>\n<\/div>\n<\/div><\/div>\n\n\n\n

\n
\n

Portfolio Dashboard<\/p>\n\n\n\n

23 Active Programs Across 4 Therapeutic Areas<\/h2>\n\n\n\n

Updated December 1, 2024. Next review scheduled for January 15, 2025.<\/p>\n<\/div>\n\n\n\n

\n
\n

Phase I<\/p>\n\n\n\n

8 compounds<\/p>\n<\/div>\n\n\n\n

\n

Phase II<\/p>\n\n\n\n

9 compounds<\/p>\n<\/div>\n\n\n\n

\n

Phase III<\/p>\n\n\n\n

6 compounds<\/p>\n<\/div>\n\n\n\n

\n

Total Investment<\/p>\n\n\n\n

\u20ac1.2 billion<\/p>\n<\/div>\n<\/div>\n\n\n\n

\n
\n

Oncology<\/p>\n\n\n\n

11<\/h3>\n\n\n\n

Active programs targeting solid tumors and hematological malignancies<\/p>\n<\/div>\n\n\n\n

\n

Immunology<\/p>\n\n\n\n

7<\/h3>\n\n\n\n

Autoimmune and inflammatory disease treatments in development<\/p>\n<\/div>\n\n\n\n

\n

Rare Diseases<\/p>\n\n\n\n

5<\/h3>\n\n\n\n

Orphan drug designations across metabolic and genetic disorders<\/p>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

\n

Lead Compound: PH-7291<\/h2>\n\n\n\n
Parameter<\/th>Value<\/th>Benchmark<\/th>Status<\/th><\/tr><\/thead>
Mechanism of Action<\/td>Selective CDK4\/6 inhibitor<\/td>\u2014<\/td>Validated<\/td><\/tr>
Target Indication<\/td>HR+\/HER2- metastatic breast cancer<\/td>\u2014<\/td>Approved<\/td><\/tr>
Half-life (t\u00bd)<\/td>28.4 hours<\/td>24\u201336 hours<\/td>\u2713 Within range<\/td><\/tr>
Bioavailability<\/td>67.3%<\/td>>50%<\/td>\u2713 Exceeds target<\/td><\/tr>
Phase III Enrollment<\/td>1,247 \/ 1,500 patients<\/td>100%<\/td>83% complete<\/td><\/tr>
Projected NDA Filing<\/td>Q3 2025<\/td>\u2014<\/td>On track<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
\n\n\n\n
\n
\n

Trial Sites by Region<\/h3>\n\n\n\n
    \n
  1. North America:<\/strong> 47 sites across the United States and Canada<\/li>\n\n\n\n
  2. Europe:<\/strong> 38 sites in Germany, France, Spain, Italy, and Poland<\/li>\n\n\n\n
  3. Asia-Pacific:<\/strong> 29 sites in Japan, South Korea, Australia, and Taiwan<\/li>\n\n\n\n
  4. Latin America:<\/strong> 12 sites in Brazil, Argentina, and Mexico<\/li>\n<\/ol>\n<\/div>\n\n\n\n
    \n

    Key Milestones<\/h3>\n\n\n\n